Edition:
United States

North China Pharmaceutical Co Ltd (600812.SS)

600812.SS on Shanghai Stock Exchange

6.48CNY
10:29pm EST
Change (% chg)

¥-0.01 (-0.15%)
Prev Close
¥6.49
Open
¥6.49
Day's High
¥6.52
Day's Low
¥6.46
Volume
2,582,789
Avg. Vol
7,682,266
52-wk High
¥9.52
52-wk Low
¥5.98

600812.SS

Chart for 600812.SS

About

North China Pharmaceutical Company. Ltd is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company's main products are classified as penicillin, cephalosporin, vitamin and other products, including bulk pharmaceuticals, finish preparations and healthcare products, among... (more)
No analyst recommendations are available for 600812.SS.

Overall

Beta: 1.07
Market Cap(Mil.): ¥10,616.54
Shares Outstanding(Mil.): 1,630.81
Dividend: 0.02
Yield (%): 0.31

Financials

  600812.SS Industry Sector
P/E (TTM): 110.64 30.04 30.65
EPS (TTM): 0.06 -- --
ROI: 1.14 15.86 15.23
ROE: 1.81 16.96 16.56

BRIEF-North China Pharma plans to issue debt financing instruments

* Says it plans to issue up to 2.0 billion yuan ($290.00 million) debt financing instruments

Nov 23 2016

BRIEF-North China Pharmaceutical and units ordered to halt production to tackle pollution

* Says it and four units in Shijiazhuang are ordered to halt production by local government as part of government efforts to tackle pollution

Nov 21 2016

BRIEF-North China Pharmaceutical gets approval for clinical trial

* Says it received approval from Food and Drug Administration Bureau on Oct. 25 for clinical trial of capecitabine tablets

Oct 26 2016

BRIEF-North China Pharmaceutical's chairman resigns

* Says Chairman Yang Haijing resigns due to change in job role

Oct 10 2016

BRIEF-North China Pharmaceutical sees 2016 Q1 to Q3 net profit outlook up 100 pct

Oct 10 North China Pharmaceutical : * Sees net profit for 2016 Q1 to Q3 up 100 percent * Says the net profit of 2015 Q1 to Q3 was 31.6 million yuan Source text in Chinese: https://goo.gl/mxqBWm Further company coverage: (Beijing Headline News)

Oct 10 2016

BRIEF-North China Pharmaceutical unit wins lawsuit

* Says its unit received judgment from United States Court of Appeals for the Second Circuit made on Sep. 20 that the court withdrew the original judgment regarding Chinese companies' vitamin C antitrust litigation and rejected the appeal from plaintiff

Sep 22 2016

BRIEF-North China Pharmaceutical unit gets nod for clinic trial

* Says its unit gets China Food and Drug Administration's approval for Tacrolimus Ointment's clinic trial

Aug 22 2016

BRIEF-North China Pharmaceutical plans to issue up to 2 bln yuan commercial paper

* Says it plans to issue up to 2.0 billion yuan ($300.64 million) commercial paper

Aug 19 2016

BRIEF-North China Pharmaceutical gets nod for clinic trial

* Says it gets China Food and Drug Administration's approval for its quetiapine fumarate extended-release tablets' clinic trial

Aug 07 2016

BRIEF-North China Pharmaceutical unit gets GMP certificate

* Says it unit receives goods manufacture practice (GMP) certificate from Hebei Food and Drug Administration

Jul 05 2016

Earnings vs. Estimates